M3 Inc is a leading provider of healthcare-related technology services in Japan. Their business model revolves around operating online platforms that connect healthcare professionals and pharmaceutical companies. M3's platforms offer various services such as medical information exchange, pharmaceutical marketing, and clinical research support. By facilitating efficient communication and collaboration among healthcare stakeholders, M3 enhances patient care and enables pharmaceutical companies to target relevant healthcare professionals effectively. With its strong presence in Japan and expansion into international markets, M3 Inc continues to revolutionize healthcare through innovative technology solutions.

M3 Inc is primarily active in the healthcare and information technology (IT) industries.

M3 Inc faces competition from various companies in the market. Some of the main competitors of M3 Inc include IQVIA Holdings Inc, Veeva Systems Inc, and Cerner Corporation. These companies offer similar products and services, targeting the healthcare industry. However, M3 Inc distinguishes itself by providing innovative solutions and platforms tailored specifically for healthcare professionals. As a trusted name in the market, M3 Inc continues to compete and thrive in the ever-evolving industry, delivering comprehensive solutions to meet the needs of healthcare professionals efficiently and effectively.

M3 Inc is a leading Japanese company specializing in healthcare services and online physician communities. Established in 2000, M3 Inc has rapidly grown to become one of the largest players in the healthcare industry. M3 Inc's innovative platform provides healthcare professionals with valuable resources, such as medical information, education, and market research opportunities. The company is committed to improving the healthcare system and enhancing patient care through its technological advancements. With a strong focus on collaboration and networking, M3 Inc continues to lead the way in revolutionizing the healthcare industry in Japan and beyond.

M3 Inc has achieved several significant milestones in its journey. One notable milestone includes the company's establishment in 2000 as a provider of medical information and services. Another milestone is the successful launch of M3's online physician community platform, MDLinx, which has grown to become one of the largest global networks of healthcare professionals. Additionally, M3 Inc expanded its reach by establishing international offices and acquiring several healthcare-related companies to enhance its product and service offerings. The company's commitment to innovation and collaboration has propelled M3 Inc to become a trusted leader in the healthcare industry.

M3 Inc is primarily present in Japan, where it is headquartered. As a leading provider of healthcare services, M3 Inc also has a strong presence in the United States, China, South Korea, and various other Asian countries. With its global reach and extensive network, M3 Inc has established a strong foothold in the medical industry, connecting healthcare professionals, pharmaceutical companies, and institutions across different countries and regions.

M3 Inc represents a set of core values and a corporate philosophy that guide its operations. As a leading company in the healthcare industry, M3 Inc focuses on three key values: innovation, integrity, and impact. With a commitment to delivering innovative solutions and services, M3 Inc strives to stay at the forefront of advancements in healthcare technology. The company's strong emphasis on integrity ensures transparent and ethical conduct in all business dealings. Moreover, M3 Inc aims to create a positive impact on healthcare professionals and society as a whole through its products and services. These values and corporate philosophy drive M3 Inc's mission to improve healthcare globally.

Analysts currently set an average price target of 2,673.18 JPY for the M3 stock (median: 2,652.00 JPY), implying +47.5 % versus the latest price. The consensus is based on 19 analyst ratings.

M3 Analyst Price Targets 2026

19 analysts currently rate the M3 stock: 13 recommend buying, 6 holding and 0 selling. For 2026, analysts expect M3 to generate revenue of 363.14 B JPY and earnings per share of 75.32 JPY.

M3 Analyst Price Targets 2026

Converted at the current exchange rate, the M3 share trades at 9.87 EUR (1,839.00 JPY).

The M3 share (2413.T) is listed on 6 stock exchanges, including: Frankfurt (4YC.F), München (4YC.MU), Düsseldorf (4YC.DU).

M3 Inc is a leading company in the healthcare IT and medical services industry. Their business model is based on various divisions, including providing online networks for doctors, medical imaging, e-health, clinical research, and pharmaceutical advertising. One of M3's main activities is providing online networks for doctors, including their flagship product M3.com. The network serves as a discussion forum, continuing education platform, and market research tool for doctors. It allows doctors to connect with colleagues, access scientific research, and participate in clinical trials. The platform also offers a specialized job board for medical professionals. Medical imaging is a key business area for M3. They offer radiology solutions for hospitals and clinics, including a complete workflow management platform and a PACS (Picture Archiving and Communication System) for storing, transmitting, and archiving medical images. The company also provides point-of-care systems for quick diagnosis and treatment of patients. Another focus is e-health. Here, M3 offers a variety of products and services, including the development of mobile and web-based applications that collect, store, and analyze health data. Such solutions include telemedicine, patient portals, online medical records, and patient apps designed to facilitate daily care. Clinical research is another important business field for M3. The company provides a platform for patient recruitment for clinical studies. They work closely with pharmaceutical and biotech companies to accelerate patient access and streamline the clinical research process. This platform enables doctors to directly contact potential patients who may be eligible for a specific clinical trial. Finally, M3 is also involved in pharmaceutical advertising and sales promotion. The company offers a variety of marketing solutions for pharmaceutical and biotech firms, including internet advertising, direct marketing via email, telephone marketing, and other digital or social media. Additionally, the company has comprehensive market research tools that allow its clients to obtain accurate analysis of the healthcare industry. In summary, M3 offers a wide range of products and services in the field of medical services and healthcare IT. The company has a strong presence in Japan and is also expanding into other countries, particularly the United States and Europe. With its comprehensive product range and strong market position, M3 is well positioned to benefit from the strong growth of the healthcare sector worldwide.

The expected revenue of M3 is 363.14 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of M3 is 51.14 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of M3 is currently 24.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the M3 stock.

The price-to-sales ratio (P/S) of M3 is currently 3.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the M3 stock.

The Eulerpool Quality Score for M3 is 7/10.

The ISIN of M3 is JP3435750009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of M3 is A0B8RE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of M3 is 2413.T. The ticker symbol is used to trade M3 shares on the stock exchange.

Over the past 12 months, M3 paid a dividend of 21.00 JPY . This corresponds to a dividend yield of about 1.14 %. For the coming 12 months, M3 is expected to pay a dividend of 42.00 JPY.

The current dividend yield of M3 is 1.14 %.

M3 pays a dividend, distributed in the months of , , , .

M3 paid dividends every year for the past 18 years.

For the upcoming 12 months, dividends amounting to 42.00 JPY are expected. This corresponds to a dividend yield of 2.28 %.

M3 is assigned to the 'Health' sector.

To receive the latest dividend of M3 from amounting to 21 JPY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, M3 distributed 19 JPY as dividends.

The dividends of M3 are distributed in JPY.